Companies House 2024-04-01 2025-03-31 2025-03-31 false true iso4217:GBP xbrli:pure 09924529 2023-04-01 2024-03-31 09924529 2025-03-31 09924529 2024-04-01 2025-03-31 09924529 2024-03-31 09924529 curr:PoundSterling 2024-04-01 2025-03-31 09924529 uk-bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 09924529 uk-bus:FRS102 2024-04-01 2025-03-31 09924529 uk-bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 09924529 uk-bus:AbridgedAccounts 2024-04-01 2025-03-31 09924529 uk-bus:RegisteredOffice 2024-04-01 2025-03-31 09924529 uk-bus:Director40 2024-04-01 2025-03-31 09924529 uk-bus:Director1 2024-04-01 2025-03-31 09924529 uk-bus:Director2 2024-04-01 2025-03-31 09924529 uk-bus:Director3 2024-04-01 2025-03-31 09924529 uk-bus:Director4 2024-04-01 2025-03-31 09924529 uk-bus:Director5 2024-04-01 2025-03-31 09924529 uk-bus:Director6 2024-04-01 2025-03-31 09924529 uk-bus:Director7 2024-04-01 2025-03-31 09924529 uk-bus:Director8 2024-04-01 2025-03-31 09924529 uk-bus:Director9 2024-04-01 2025-03-31 09924529 uk-bus:Director10 2024-04-01 2025-03-31 09924529 uk-bus:Director11 2024-04-01 2025-03-31 09924529 uk-bus:Director12 2024-04-01 2025-03-31 09924529 uk-bus:Director13 2024-04-01 2025-03-31 09924529 uk-bus:Director14 2024-04-01 2025-03-31 09924529 uk-bus:Director15 2024-04-01 2025-03-31 09924529 uk-bus:Director16 2024-04-01 2025-03-31 09924529 uk-bus:Director17 2024-04-01 2025-03-31 09924529 uk-bus:Director18 2024-04-01 2025-03-31 09924529 uk-bus:Director19 2024-04-01 2025-03-31 09924529 uk-bus:Director20 2024-04-01 2025-03-31 09924529 uk-bus:CompanySecretary1 2024-04-01 2025-03-31 09924529 core:AfterOneYear 2025-03-31 09924529 core:AfterOneYear 2024-03-31 09924529 core:WithinOneYear 2025-03-31 09924529 core:WithinOneYear 2024-03-31 09924529 core:WithinOneYear 2024-04-01 2025-03-31 09924529 core:AfterOneYear 2025-03-31 09924529 core:AfterOneYear 2024-03-31 09924529 core:AfterOneYear 2024-04-01 2025-03-31 09924529 core:ShareCapital 2025-03-31 09924529 core:ShareCapital 2024-03-31 09924529 core:SharePremium 2025-03-31 09924529 core:SharePremium 2024-03-31 09924529 core:OtherReservesSubtotal 2025-03-31 09924529 core:OtherReservesSubtotal 2024-03-31 09924529 core:RevaluationReserve 2025-03-31 09924529 core:RevaluationReserve 2024-03-31 09924529 core:RetainedEarningsAccumulatedLosses 2025-03-31 09924529 core:RetainedEarningsAccumulatedLosses 2024-03-31 09924529 core:Associate1 2024-04-01 2025-03-31 09924529 core:Associate1 2024-03-31 09924529 core:Associate1 2025-03-31 09924529 core:Associate2 2024-04-01 2025-03-31 09924529 core:Associate2 2024-03-31 09924529 core:Associate2 2025-03-31 09924529 core:Associate3 2024-04-01 2025-03-31 09924529 core:Associate3 2024-03-31 09924529 core:Associate3 2025-03-31 09924529 core:Associate4 2024-04-01 2025-03-31 09924529 core:Associate4 2024-03-31 09924529 core:Associate4 2025-03-31 09924529 core:Associate5 2024-04-01 2025-03-31 09924529 core:Associate5 2024-03-31 09924529 core:Associate5 2025-03-31 09924529 core:Associate6 2024-04-01 2025-03-31 09924529 core:Associate6 2024-03-31 09924529 core:Associate6 2025-03-31 09924529 core:Associate7 2024-04-01 2025-03-31 09924529 core:Associate7 2024-03-31 09924529 core:Associate7 2025-03-31 09924529 core:Associate8 2024-04-01 2025-03-31 09924529 core:Associate8 2024-03-31 09924529 core:Associate8 2025-03-31 09924529 core:Associate9 2024-04-01 2025-03-31 09924529 core:Associate9 2024-03-31 09924529 core:Associate9 2025-03-31 09924529 core:Associate10 2024-04-01 2025-03-31 09924529 core:Associate10 2024-03-31 09924529 core:Associate10 2025-03-31 09924529 core:Associate11 2024-04-01 2025-03-31 09924529 core:Associate11 2024-03-31 09924529 core:Associate11 2025-03-31 09924529 core:Associate12 2024-04-01 2025-03-31 09924529 core:Associate12 2024-03-31 09924529 core:Associate12 2025-03-31 09924529 core:Associate13 2024-04-01 2025-03-31 09924529 core:Associate13 2024-03-31 09924529 core:Associate13 2025-03-31 09924529 core:Associate14 2024-04-01 2025-03-31 09924529 core:Associate14 2024-03-31 09924529 core:Associate14 2025-03-31 09924529 core:Associate15 2024-04-01 2025-03-31 09924529 core:Associate15 2024-03-31 09924529 core:Associate15 2025-03-31 09924529 core:Associate16 2024-04-01 2025-03-31 09924529 core:Associate16 2024-03-31 09924529 core:Associate16 2025-03-31 09924529 core:Associate17 2024-04-01 2025-03-31 09924529 core:Associate17 2024-03-31 09924529 core:Associate17 2025-03-31 09924529 core:Associate18 2024-04-01 2025-03-31 09924529 core:Associate18 2024-03-31 09924529 core:Associate18 2025-03-31 09924529 core:Associate19 2024-04-01 2025-03-31 09924529 core:Associate19 2024-03-31 09924529 core:Associate19 2025-03-31 09924529 core:Associate20 2024-04-01 2025-03-31 09924529 core:Associate20 2024-03-31 09924529 core:Associate20 2025-03-31 09924529 core:Associate1 2024-04-01 2025-03-31 09924529 core:Associate2 2024-04-01 2025-03-31 09924529 core:Associate3 2024-04-01 2025-03-31 09924529 core:Associate4 2024-04-01 2025-03-31 09924529 core:Associate5 2024-04-01 2025-03-31 09924529 core:Associate6 2024-04-01 2025-03-31 09924529 core:Associate7 2024-04-01 2025-03-31 09924529 core:Associate8 2024-04-01 2025-03-31 09924529 core:Associate9 2024-04-01 2025-03-31 09924529 core:Associate10 2024-04-01 2025-03-31 09924529 core:Associate11 2024-04-01 2025-03-31 09924529 core:Associate12 2024-04-01 2025-03-31 09924529 core:Associate13 2024-04-01 2025-03-31 09924529 core:Associate14 2024-04-01 2025-03-31 09924529 core:Associate15 2024-04-01 2025-03-31 09924529 core:Associate16 2024-04-01 2025-03-31 09924529 core:Associate17 2024-04-01 2025-03-31 09924529 core:Associate18 2024-04-01 2025-03-31 09924529 core:Associate19 2024-04-01 2025-03-31 09924529 core:Associate20 2024-04-01 2025-03-31 09924529 uk-bus:Director1 1 2024-04-01 2025-03-31 09924529 uk-bus:Director1 1 2024-03-31 09924529 uk-bus:Director1 1 2025-03-31 09924529 uk-bus:Director2 2 2024-04-01 2025-03-31 09924529 uk-bus:Director2 2 2024-03-31 09924529 uk-bus:Director2 2 2025-03-31 09924529 uk-bus:Director1 3 2024-04-01 2025-03-31 09924529 uk-bus:Director1 3 2024-03-31 09924529 uk-bus:Director1 3 2025-03-31 09924529 uk-bus:Director4 4 2024-04-01 2025-03-31 09924529 uk-bus:Director4 4 2024-03-31 09924529 uk-bus:Director4 4 2025-03-31 09924529 uk-bus:Director5 5 2024-04-01 2025-03-31 09924529 uk-bus:Director5 5 2024-03-31 09924529 uk-bus:Director5 5 2025-03-31 09924529 uk-bus:Director6 6 2024-04-01 2025-03-31 09924529 uk-bus:Director6 6 2024-03-31 09924529 uk-bus:Director6 6 2025-03-31 09924529 uk-bus:Director7 7 2024-04-01 2025-03-31 09924529 uk-bus:Director7 7 2024-03-31 09924529 uk-bus:Director7 7 2025-03-31 09924529 uk-bus:Director8 8 2024-04-01 2025-03-31 09924529 uk-bus:Director8 8 2024-03-31 09924529 uk-bus:Director8 8 2025-03-31 09924529 uk-bus:Director9 9 2024-04-01 2025-03-31 09924529 uk-bus:Director9 9 2024-03-31 09924529 uk-bus:Director9 9 2025-03-31 09924529 uk-bus:Director10 10 2024-04-01 2025-03-31 09924529 uk-bus:Director10 10 2024-03-31 09924529 uk-bus:Director10 10 2025-03-31 09924529 uk-bus:Director11 11 2024-04-01 2025-03-31 09924529 uk-bus:Director11 11 2024-03-31 09924529 uk-bus:Director11 11 2025-03-31 09924529 uk-bus:Director12 12 2024-04-01 2025-03-31 09924529 uk-bus:Director12 12 2024-03-31 09924529 uk-bus:Director12 12 2025-03-31 09924529 uk-bus:Director13 13 2024-04-01 2025-03-31 09924529 uk-bus:Director13 13 2024-03-31 09924529 uk-bus:Director13 13 2025-03-31 09924529 uk-bus:Director14 14 2024-04-01 2025-03-31 09924529 uk-bus:Director14 14 2024-03-31 09924529 uk-bus:Director14 14 2025-03-31 09924529 uk-bus:Director15 15 2024-04-01 2025-03-31 09924529 uk-bus:Director15 15 2024-03-31 09924529 uk-bus:Director15 15 2025-03-31 09924529 uk-bus:Director16 16 2024-04-01 2025-03-31 09924529 uk-bus:Director16 16 2024-03-31 09924529 uk-bus:Director16 16 2025-03-31 09924529 uk-bus:Director17 17 2024-04-01 2025-03-31 09924529 uk-bus:Director17 17 2024-03-31 09924529 uk-bus:Director17 17 2025-03-31 09924529 uk-bus:Director18 18 2024-04-01 2025-03-31 09924529 uk-bus:Director18 18 2024-03-31 09924529 uk-bus:Director18 18 2025-03-31 09924529 uk-bus:Director19 19 2024-04-01 2025-03-31 09924529 uk-bus:Director19 19 2024-03-31 09924529 uk-bus:Director19 19 2025-03-31 09924529 uk-bus:Director20 20 2024-04-01 2025-03-31 09924529 uk-bus:Director20 20 2024-03-31 09924529 uk-bus:Director20 20 2025-03-31 09924529 1 2024-04-01 2025-03-31 09924529 2 2024-04-01 2025-03-31 09924529 3 2024-04-01 2025-03-31

# PURPLE ORCHID HEALTH LTD

## Company Registration Number:
09924529 (England and Wales)

## Unaudited abridged accounts for the year ended 31 March 2025

## Period of accounts

## Start date: 01 April 2024

## End date: 31 March 2025

# PURPLE ORCHID HEALTH LTD

## Contents of the Financial Statements

for the Period Ended 31 March 2025

Balance sheet |
Notes |

# PURPLE ORCHID HEALTH LTD

## Balance sheet

As at 31 March 2025

| Notes | 2025 | 2024
--- | --- | --- | ---
|  | £ | £
Called up share capital not paid: |  | 0 | 0
Fixed assets
Intangible assets: |  | 0 | 0
Tangible assets: | 3 | 1,982 | 1,614
Investments: |  | 0 | 0
Total fixed assets: |  | 1,982 | 1,614
Current assets
Stocks: |  | 145,024 | 170,128
Debtors: |  | 198,280 | 230,465
Cash at bank and in hand: |  | 90,238 | 21,321
Investments: |  | 0 | 0
Total current assets: |  | 433,542 | 421,914
Creditors: amounts falling due within one year: |  | (340,923) | (379,019)
Net current assets (liabilities): |  | 92,619 | 42,895
Total assets less current liabilities: |  | 94,601 | 44,509
Creditors: amounts falling due after more than one year: |  | (23,815) | (29,210)
Provision for liabilities: |  |  | 0
Total net assets (liabilities): |  | 70,786 | 15,299
Capital and reserves
Called up share capital: |  | 96,484 | 96,484
Share premium account: |  | 0 | 0
Revaluation reserve: |  | 0 | 0
Other reserves: |  | 0 | 0
Profit and loss account: |  | (25,698) | (81,185)
Shareholders funds: |  | 70,786 | 15,299

The notes form part of these financial statements

# PURPLE ORCHID HEALTH LTD

## Balance sheet statements

For the year ending 31 March 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 29 October 2025
and signed on behalf of the board by:

Name: Karen Gardiner
Status: Director

The notes form part of these financial statements

# PURPLE ORCHID HEALTH LTD

## Notes to the Financial Statements

for the Period Ended 31 March 2025

## 1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

## Turnover policy

Revenue is measured at the fair value of the consideration received or receivable. Revenue is reduced for estimated customer returns, rebates and other similar allowances. Revenue from the sale of goods is recognised when goods are delivered and legal title has passed.

## Tangible fixed assets and depreciation policy

Tangible fixed assets held for company’s own use are stated at the cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided at the rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful life on a straight-line basis at rate 25% per annum. Assets held under finance leases are depreciated in the same way as owned assets. At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss., if any. Where it is not possible to estimate the recoverable amount of the asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

## Valuation and information policy

Stocks are stated at the lower of cost and the estimated selling price less costs to complete and sell (net realisable value). Costs, which compromise direct production costs, are based on the method most appropriate to the type of the inventory class, but usually on the first-in-first-out basis. Overheads are charged to profit or loss as incurred. Net realisable value is based on the estimated selling price less any estimated completion or selling costs. When stocks are sold, the carrying amount of those stocks is recognised as an expense in the period in which the related revenue is recognised. The amount of any write-down of stocks to net realisable value and all losses of stocks are recognised as an expense in the period in which the write-down or loss occurs. The amount of any reversal of any write-down of stock is recognised as a reduction in the amount of stocks recognised as an expense in the period in which the reversal occurs.

## Other accounting policies

Cash at bank and in hand Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at the call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities. Financial Instruments The company has elected to apply the provision of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments. Financial instruments are recognised in the company’s statement of financial position when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Equity instruments Equity instruments issued by the company are recorded at the proceeds received, net of direct issue cost. Dividends payable on the equity instruments are recognised as liabilities once they are no longer at the discretion of the company. Foreign currencies Transactions in currencies, other than functional currency of the company, are recorded at the rate of exchange on the date of the transaction occurred. Monetary items denominated in other currencies are translated at the rate prevailing at the end of the reporting period. All differences are taken to the profit and loss account. Non-monetary items that are measured at historic cost in a foreign currency are not retranslated. Taxation Taxation represents the sum of tax currently payable and deferred tax. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax is recognised on all timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Pensions The company operates a defined contribution pension scheme, and the pension charge represents the amounts payable by the company to the fund in respect of the year. Employee benefits The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets. The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received. Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

# PURPLE ORCHID HEALTH LTD

## Notes to the Financial Statements

for the Period Ended 31 March 2025

## 2. Employees

| 2025 | 2024
--- | --- | ---
Average number of employees during the period | 4 | 4

# PURPLE ORCHID HEALTH LTD

## Notes to the Financial Statements

for the Period Ended 31 March 2025

## 3. Tangible Assets

| Total
--- | ---
Cost | £
At 01 April 2024 | 5,839
Additions | 1,838
Disposals | (1,325)
Revaluations | 0
Transfers | 0
At 31 March 2025 | 6,352
Depreciation |
At 01 April 2024 | 4,225
Charge for year | 1,470
On disposals | (1,325)
Other adjustments | 0
At 31 March 2025 | 4,370
Net book value |
At 31 March 2025 | 1,982
At 31 March 2024 | 1,614